These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28687872)

  • 1. High-frequency aflibercept injections in persistent neovascular age-related macular degeneration.
    Călugăru D; Călugăru M
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2067-2068. PubMed ID: 28687872
    [No Abstract]   [Full Text] [Related]  

  • 2. High-frequency aflibercept injections in persistent neovascular age-related macular degeneration.
    Muftuoglu IK; Freeman WR
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2069. PubMed ID: 28780686
    [No Abstract]   [Full Text] [Related]  

  • 3. Short-Term Changes in Choroidal Thickness After Aflibercept Therapy for Neovascular Age-Related Macular Degeneration.
    Uzun S; Pehlivan E
    Am J Ophthalmol; 2016 Aug; 168():287. PubMed ID: 27262619
    [No Abstract]   [Full Text] [Related]  

  • 4. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
    Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
    Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
    Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results.
    Homer N; Grewal DS; Mirza RG; Lyon AT; Gill MK
    Eye (Lond); 2015 Sep; 29(9):1152-5. PubMed ID: 26021870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
    Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
    Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
    Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.
    Venkatesh R; Dave PA; Singh S; Gurav P; Gujral G
    Am J Ophthalmol; 2016 Oct; 170():246-247. PubMed ID: 27594519
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.
    Călugăru D; Călugăru M
    Am J Ophthalmol; 2017 Jan; 173():145-146. PubMed ID: 27842696
    [No Abstract]   [Full Text] [Related]  

  • 13. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
    de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I
    Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
    Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
    Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration.
    Uzun S; Pehlivan E
    Graefes Arch Clin Exp Ophthalmol; 2016 Oct; 254(10):2065-2066. PubMed ID: 27251193
    [No Abstract]   [Full Text] [Related]  

  • 16. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept.
    Gharbiya M; Cruciani F; Mariotti C; Grandinetti F; Marenco M; Cacace V
    J Ocul Pharmacol Ther; 2015; 31(6):357-62. PubMed ID: 26133059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to the letter to the editor: Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration.
    Yun C; Oh J
    Graefes Arch Clin Exp Ophthalmol; 2016 Oct; 254(10):2067. PubMed ID: 27282873
    [No Abstract]   [Full Text] [Related]  

  • 19. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
    Schmidt-Erfurth U; Kaiser PK; Korobelnik JF; Brown DM; Chong V; Nguyen QD; Ho AC; Ogura Y; Simader C; Jaffe GJ; Slakter JS; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Sowade O; Zeitz O; Norenberg C; Sandbrink R; Heier JS
    Ophthalmology; 2014 Jan; 121(1):193-201. PubMed ID: 24084500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.